[Analysis of population pharmacokinetics with NONMEM in clinical patients treated with amikacin by intravenous infusion].
Clinical data (n = 275) collected from 52 patients with respiratory tract infection receiving amikacin (AMK) by intravenous infusion were analysed with NONMEM, a computer program designed for estimating population pharmacokinetic parameters. Concentrations of AMK in serum were determined by fluorescence polarization immunoassay (FPIA). A two compartment open model was used for analysing AMK population pharmacokinetics. The influence of body weight (BW), creatinine clearance (CC), administration history (HIS) and state of pathology (chronic obstructional pulmonary disease, COPD) on pharmacokinetics was investigated. The pharmacokinetic parameters of AMK were shown to be influenced by creatinine clearance (CC) and COPD.
Chu
X M
XM
Department of Clinical Pharmacology, General Hospital of Armed Forces, Nanjing.
Rui
J Z
JZ
Zhou
Y G
YG
Dai
Y J
YJ
Cai
W M
WM
Ling
S S
SS
D000328:Adult; D000368:Aged; D000583:Amikacin / Q000493:pharmacokinetics*; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics*; D003404:Creatinine / Q000097:blood; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008173:Lung Diseases, Obstructive / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D017711:Nonlinear Dynamics; D012141:Respiratory Tract Infections / Q000378:metabolism*
D000900:Anti-Bacterial Agents; D000583:Amikacin; D003404:Creatinine